Navigation Links


Ribonuclease in Medical News

Enzyme with a sugar antenna

... Angewandte Chemie , scientists led by Carlo Unverzagt at the University of Bayreuth (Germany) have now successfully used a new strategy to synthesize ribonuclease C (RNase C), a glycosylated bovine pancreatic enzyme. Sugar components play an important role in the water solubility, stability, and folding of ...

Alfacell Announces Management Update

... end of January 2009. About ONCONASE (R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Reports Financial Results for First Quarter of Fiscal 2009

... planned NDA submission. About ONCONASE (R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Brain Tumor Drug in Frogs A New Report

... of the future.Amphinase is a version of a ribonuclease enzyme that has been isolated from the oocytes ... in the future.Amphinase is the second anti-tumour ribonuclease to be isolated by Alfacell Corporation from Rana ... and understanding of our family of novel ribonuclease based therapeutics with the potential to help ...
Ribonuclease in Medical Technology

Alfacell Provides Shareholder Update

... Chief Operating Officer About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Provides ONCONASE(R) NDA Submission Update

... submission of its NDA. About ONCONASE (R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines

... role in treating the disease." About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel

... with Megapharm." About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial

... Web site at http://www.alfacell.com . About ONCONASE(R) ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell's ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment

... in, and confounds the treatment of NSCLC." About ONCONASE(R) ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)

... and to bring them forward into the clinic." About ONCONASE(R) ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program

... and receive at least one dose of study drug. About ONCONASE(R) ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Reports Financial Results for First Quarter of Fiscal 2008

... site at http://www.alfacell.com . About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program

... to discuss the company's fiscal 2007 performance. About ONCONASE(R) ONCONASE is a first-in-class product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

More>>

Ribonuclease in Biological Technology

Alfacell Provides ONCONASE(R) NDA Submission Update

... as of January 1, 2009. About ONCONASE (R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell's ONCONASE(R) and R-Amphinase Show Anti-Tumor Activity in Chronic Lymphocytic Leukemia and Acute Myeloblastic Leukemia Cells

... in this disease. About ONCONASE (R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Reports Fiscal Fourth Quarter and Full Year 2008 Financial Results

... clinical development program." About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Paper in Cell Cycle Reports Alfacell's ONCONASE(R) Targets siRNA

... that failed prior chemotherapy." About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Hires Advisors to Advance Strategic Alternatives

... has approved a specific transaction. About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Reports Financial Results for Third Quarter of Fiscal 2008

... site at http://www.alfacell.com . About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Announces Retirement of Chief Executive Officer

... foundation she has built for us." About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Reports Financial Results for Second Quarter of Fiscal 2008

... site at http://www.alfacell.com . About ONCONASE(R) ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell Announces ONCONASE(R) Purchase and Supply Agreement with Scientific Protein Laboratories

... and straight through to commercial launch. About ONCONASE(R) ONCONASE is a first-in-class product candidate from Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells ...

Alfacell to Host Webinar on RNA Interference-Like Mechanics of RNase Therapeutics on Nov. 29

... will Include World-Renowned RNase and RNA Researchers SOMERSET, N.J., Oct. 25 /PRNewswire-FirstCall/ -- The RNA interference- like mechanics of ribonuclease (RNase) therapeutics will be the focus of scientific presentations in a Nov. 29 Webinar hosted by Alfacell Corporation (Nasdaq: ACEL ). Moderated ...

More>>

Ribonuclease in Biological Products

RNase ONE™ Ribonuclease from Promega

Description:... RNase ONE ribonuclease is a 27kDa periplasmic enzyme from E. coli that ... of these intermediates to 3-NMPs (1). RNase ONE ribonuclease is one of the few known RNases that can cleave a ... between any two ribonucleotides (1,2). RNase ONE ribonuclease may be used to remove RNA from DNA preparations, ...
Company:Promega

ANTI-RNase from Ambion

Description:... ANTI-RNase is a protein ribonuclease inhibitor that noncovalently binds and ... CL3. ANTI-RNase is distinct from human placental ribonuclease inhibitor in that it has a more robust ... may be used in any application where placental ribonuclease inhibitor is used. It is ideal for use in in ...
Company:Ambion

RNase Inhibitor (Cloned) from Ambion

Description:... in many tissues and cell types. Addition of the ribonuclease inhibitor has been shown to be useful whenever ... and preparation of RNase-free antibodies. ribonuclease inhibitor does not inhibit RNase 1, T1, T2, H, U1, U2 or CL3. ribonuclease inhibitor requires a minimum of 1 mM DTT to ...
Company:Ambion

Recombinant RNasin® Ribonuclease Inhibitor from Promega

Description:... Natural and Recombinant RNasin ribonuclease Inhibitors have broad spectrum RNase inhibitory ... 1:1 ratio. The Ki value for the binding of RNasin ribonuclease Inhibitor to RNase (e.g., RNase A) is ... offers two different preparations: Natural RNasin ribonuclease Inhibitor(a) and Recombinant ...
Company:Promega

SUPERaseIn from Ambion

Description:... against degradation. The most widely used RNase inhibitor is placental ribonuclease inhibitor (RIP). SUPERaseIn is distinct from RIP in that it has a more ... absence of DTT, and inhibits a broader range of RNases. While placental ribonuclease inhibitors are effective only against RNase A type enzymes, SUPERaseIn ...
Company:Ambion

RNaseOUT Recombinant Ribonuclease Inhibitor from Invitrogen

Description:... RNaseOUT Recombinant ribonuclease Inhibitor is a potent noncompetitive inhibitor of pancreatic-type ribonucleases such as RNase A. Like other RNase inhibitors RNaseOUT Recombinant ribonuclease Inhibitor is an acidic protein with a molecular weight ~52 kDa. RNaseOUT ...
Company:Invitrogen

MAXIscript SP6/T7 Kit from Ambion

Description:... Kits synthesize RNA probes with specific activities reaching 1 x 10 9 cpm/g. High specific activity, single-stranded RNA probes are used in ribonuclease protection assays, in situ hybridization, and blot hybridizations. MAXIscript Kits can also be used for the synthesis of modest amounts of unlabeled ...
Company:Ambion

5X MEGAscript® T7 Kit from Ambion

Description:... incorporates many modified nucleotides Kits specific for templates with T7, T3 and SP6 RNA polymerase promoters All kits contain SUPERaseIn ribonuclease Inhibitor ...
Company:Ambion

HIV Volume 2 (Biochemistry, Molecular Biology and Drug Discovery) from Promega

Description:... information, detailed practical information and methods for the study of major HIV proteins including: the HIV growth cycle; reverse transcriptase, ribonuclease H, integrase and protease. Expression of HIV proteins using baculoviruses; RNA binding assays; Tat and Rev assays; HIV/CD4 interactions; transient ...
Company:Promega

StabMRT Maxi Kit from RNAworks

Description:... molecular biology applications including storage, transport, handling, analysis by gel electrophoresis, Agilent Bioanalyser 2100, mass spectrometry, ribonuclease protection assays and Northern blotting. Protocols on line on RNAworks website A free MRT-RNA sample is available on request from RNAworks. ...
Company:RNAworks

More>>

Ribonuclease in Biological Dictionary

RNase

... ribonuclease (commonly abbreviated RNase ) is a type of ... turnover ribozymes in nature (the other ... ribonuclease P ( RNase P) is a type of ribonuclease which cleaves RNA. RNase P is unique from other ...

Ribonuclease

... ribonuclease is a type of nuclease that catalyzes the ... several sub-classes within the EC ... ribonuclease A (RNase A) is an endonuclease that cleaves ... classic model systems of protein science. ribonuclease summary with 8 pages of encyclopedia entries, ...

Tertiary Structure

... of protein tertiary structure (Ab Initio) ... The tertiary structure of proteins is maintained by a host of weak, non-covalent ... ribonuclease has several disulphide bonds stabilising its tertiary structure . ... Tertiary structure is stabilized by noncovalent interactions and, in ...

More>>

Other Contentsconsumersconsumersconsumersconsumersconsumersconsumerscontigcontractilecontractilecontractilecontractilecontiguousconvergenceconvergenceconvergenceconvergencecontrolcontrolcontrolcontrolcontrolcontrolcontrolcontrolcontrolcontrolnumbernumbernumbernumbernumbernumbernumbernumbernumbernumber
Breaking Medicine News(10 mins):Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 2Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 3Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 4Health News:Pharmacyclics, Inc. Announces Presentation of Interim Results From Phase I Trial of Its First-In-Human Btk Inhibitor PCI-32765 5Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 2Health News:Health Care Without Harm Applauds EPA Finding Climate Change is Danger to Public Health 3Health News:Don't I know you? University of Toronto research sheds light on memorial retrieval 2Health News:Antidepressants May Change Your Personality 2Health News:Antidepressants May Change Your Personality 3Health News:Antidepressants May Change Your Personality 4
Other TagsShopShopShopShinShinShinShinAttaAttaAttaAttaAttaOther Tagsretention 2retention 3motherhood 2surrogate 2others 2others 3others 4others 5others 6others 7others 8others 9others 10perspective 2perspective 3perspective 4visual 2visual 3visual 4visual 5visual 6visual 7monkeys 2monkeys 3monkeys 4rhesus 2